跳至主要内容
临床试验/EUCTR2008-008251-42-NL
EUCTR2008-008251-42-NL进行中(未招募)不适用

Clinical and immunological effects of imiquimod and HPV-vaccination compared to imiquimod alone in female patients with Usual type VIN - Effects of HPV-vaccination and imiquimod in VIN patients

Erasmus MC0 个研究点开始时间: 2009年1月5日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Erasmus MC

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • -Histological proven usual type VIN, without invasion
  • -Previous treatment with imiquimod for 12-16 weeks with a partial response to
  • imiquimod treatment defined as a reduction in lesion size of 26%-99%
  • -The patient is willing to use a medically acceptable method of contraception throughout the study
  • -Age 18 and above
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -(Micro-)invasive carcinoma
  • -Pregnancy and/or breastfeeding
  • -Past history of vulvar cancer
  • -Differentiated (non HPV-related) VIN
  • -Other treatment of VIN or anogenital warts within 1 month of start trial
  • -Hypersensitivity to any components of the vaccine or cream formulation
  • -History of psoriasis or other inflammatory dermatosis of the vulva
  • -Immunodeficiency (e.g. HIV, systemic corticosteroid use)
  • -Insufficient understanding of the Dutch language
  • -Partial responders who are disease-free at study-entry due to other treatment of VIN

研究者

发起方
Erasmus MC

相似试验